Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Standard

Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. / Vinkel, Caroline; Thomsen, Simon F.

I: International Journal of Dermatology, Bind 56, Nr. 8, 08.2017, s. 811-818.

Publikation: Bidrag til tidsskriftReviewForskningfagfællebedømt

Harvard

Vinkel, C & Thomsen, SF 2017, 'Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne', International Journal of Dermatology, bind 56, nr. 8, s. 811-818. https://doi.org/10.1111/ijd.13603

APA

Vinkel, C., & Thomsen, S. F. (2017). Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. International Journal of Dermatology, 56(8), 811-818. https://doi.org/10.1111/ijd.13603

Vancouver

Vinkel C, Thomsen SF. Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. International Journal of Dermatology. 2017 aug;56(8):811-818. https://doi.org/10.1111/ijd.13603

Author

Vinkel, Caroline ; Thomsen, Simon F. / Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne. I: International Journal of Dermatology. 2017 ; Bind 56, Nr. 8. s. 811-818.

Bibtex

@article{5ffe333fd4ae47da940f9ced78c1a57a,
title = "Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne",
abstract = "Autoinflammatory syndromes associated with hidradenitis suppurativa (HS) and/or acne are rare but potentially debilitating disorders if not diagnosed and treated correctly. They share a common pathogenesis involving a dysregulated innate immune system with abnormal interleukin (IL)-1 signaling leading to sterile neutrophilic inflammation. The clinical features are recurrent episodes of fever, painful arthritis, and skin lesions consistent with HS, acne, and pyoderma gangrenosum (PG) accompanied by elevated systemic inflammatory markers in blood. So far, several clinically different syndromes have been reported in the literature including pyoderma gangrenosum, acne, and pyogenic arthritis (PAPA), pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH), pyoderma gangrenosum, acne, and spondyloarthritis (PASS), pyoderma gangrenosum, acne, pyogenic arthritis, and hidradenitis suppurativa (PAPASH), psoriatic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PsAPASH), and pyoderma gangrenosum, acne, and ulcerative colitis (PAC). The rarity of the syndromes complicates the establishment of evidence-based treatment guidelines. Furthermore, treatment can be challenging due to lack of response to standard treatment modalities. Therefore, it is important to increase the awareness about these diseases in order to optimize disease management and ultimately improve the quality of life of patients.",
author = "Caroline Vinkel and Thomsen, {Simon F.}",
year = "2017",
month = aug,
doi = "10.1111/ijd.13603",
language = "English",
volume = "56",
pages = "811--818",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - Autoinflammatory syndromes associated with hidradenitis suppurativa and/or acne

AU - Vinkel, Caroline

AU - Thomsen, Simon F.

PY - 2017/8

Y1 - 2017/8

N2 - Autoinflammatory syndromes associated with hidradenitis suppurativa (HS) and/or acne are rare but potentially debilitating disorders if not diagnosed and treated correctly. They share a common pathogenesis involving a dysregulated innate immune system with abnormal interleukin (IL)-1 signaling leading to sterile neutrophilic inflammation. The clinical features are recurrent episodes of fever, painful arthritis, and skin lesions consistent with HS, acne, and pyoderma gangrenosum (PG) accompanied by elevated systemic inflammatory markers in blood. So far, several clinically different syndromes have been reported in the literature including pyoderma gangrenosum, acne, and pyogenic arthritis (PAPA), pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH), pyoderma gangrenosum, acne, and spondyloarthritis (PASS), pyoderma gangrenosum, acne, pyogenic arthritis, and hidradenitis suppurativa (PAPASH), psoriatic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PsAPASH), and pyoderma gangrenosum, acne, and ulcerative colitis (PAC). The rarity of the syndromes complicates the establishment of evidence-based treatment guidelines. Furthermore, treatment can be challenging due to lack of response to standard treatment modalities. Therefore, it is important to increase the awareness about these diseases in order to optimize disease management and ultimately improve the quality of life of patients.

AB - Autoinflammatory syndromes associated with hidradenitis suppurativa (HS) and/or acne are rare but potentially debilitating disorders if not diagnosed and treated correctly. They share a common pathogenesis involving a dysregulated innate immune system with abnormal interleukin (IL)-1 signaling leading to sterile neutrophilic inflammation. The clinical features are recurrent episodes of fever, painful arthritis, and skin lesions consistent with HS, acne, and pyoderma gangrenosum (PG) accompanied by elevated systemic inflammatory markers in blood. So far, several clinically different syndromes have been reported in the literature including pyoderma gangrenosum, acne, and pyogenic arthritis (PAPA), pyoderma gangrenosum, acne, and hidradenitis suppurativa (PASH), pyoderma gangrenosum, acne, and spondyloarthritis (PASS), pyoderma gangrenosum, acne, pyogenic arthritis, and hidradenitis suppurativa (PAPASH), psoriatic arthritis, pyoderma gangrenosum, acne, and hidradenitis suppurativa (PsAPASH), and pyoderma gangrenosum, acne, and ulcerative colitis (PAC). The rarity of the syndromes complicates the establishment of evidence-based treatment guidelines. Furthermore, treatment can be challenging due to lack of response to standard treatment modalities. Therefore, it is important to increase the awareness about these diseases in order to optimize disease management and ultimately improve the quality of life of patients.

U2 - 10.1111/ijd.13603

DO - 10.1111/ijd.13603

M3 - Review

C2 - 28345207

AN - SCOPUS:85017159847

VL - 56

SP - 811

EP - 818

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 8

ER -

ID: 196716100